|
|
||||||||
From the Department of Anesthesiology (Dr. Dworkin), College of Physicians and Surgeons, Columbia University, New York; Department of Neurology (Dr. Bates), Royal Victoria Infirmary, Newcastle upon Tyne, England; Department of Neurology (Dr. Millar), Royal Victoria and Claremont Street Hospitals, Belfast, Northern Ireland; and Division of Neurology (Dr. Paty), University of British Columbia, Vancouver, Canada.
Data from three double-blind trials of linoleic acid in the treatment of multiple sclerosis (MS) were reanalyzed to examine whether inconsistency in the results was due to a relationship between patient Characteristics and treatment response. The combined data consisted of neurologic assessments over 2/1,2-year trials for 87 treated patients and 85 control patients. Treated patients with minimal or no disability at entry had a smaller increase in disability than did controls (P < 0.05). In addition, treatment reduced the severity and duration of relapses at all levels of disability and duration of illness at entry to the trials.
Address correspondence and reprint requests to Dr. Dworkin, Department of Anesthesiology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032.
Supported in part by the National Multiple Sclerosis Society.
Accepted for publication March 13, 1984.
This article has been cited by other articles:
![]() |
S. Schwarz and H. Leweling Multiple sclerosis and nutrition Multiple Sclerosis, February 1, 2005; 11(1): 24 - 32. [Abstract] [PDF] |
||||
![]() |
G. M. Franklin and L. Nelson Environmental risk factors in multiple sclerosis: Causes, triggers, and patient autonomy Neurology, October 28, 2003; 61(8): 1032 - 1034. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |